Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question

• M. Sureda ^[2] ; E. Calvo ^[1] ; J. J. Mata ^[2] ; V. Escudero Ortiz ^[2] ; E. Martinez Navarro ^[2] ; A. Catalán ^[2] ; J. Rebollo ^[2]
  1. [1] Hospital Universitario HM Sanchinarro

     Hospital Universitario HM Sanchinarro

     Madrid, España

     
  2. [2] Plataforma de Oncología, Hospital Quironsalud Torrevieja, C/Partida de la Loma s/n, 03184 Torrevieja, Alicante, Spain
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 8, 2021, págs. 1511-1519
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Discovery and clinical development of monoclonal antibodies with the ability to interfere in the regulation of the immune response have significantly changed the landscape of oncology in recent years. Among the active agents licensed by the regulatory agencies, nivolumab and pembrolizumab are paradigmatic as the most relevant ones according to the magnitude of available data derived from the extensive preclinical and clinical experience. Although in both cases the respective data sheets indicate well-defined dosage regimens, a review of the literature permits to verify the existence of many issues still unresolved about dosing the two agents, so it must be considered an open question of potentially important consequences, in which to work to improve the effectiveness and efficiency of use.